Alcresta
Massachusetts, US · Founded 2011 · Delaware corporation · 106 employees on LinkedIn · 4 known investors
Find your way into Alcresta
266 people in our graph share verified history with the Alcresta team — schools, employers, funds. One of them is your warm intro.
Ben Lererunlockedknows Martin Paz · together at University of Pennsylvania (overlapped)
×8knows the team · via University of Pennsylvania
×2knows the team · via Université de Montréal
knows the team · via Texas State University
Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases. The company is based in Massachusetts and focuses on delivering novel enzymatic solutions within the biotechnology and pharmaceutical sector.
Founders & leadership
DO
Daniel OrlandoinChief Executive Officer
TK
Tasos KonidarisinChief Financial Officer2016–2020
MP
Martin PazinChief Human Resources Officer2016–2018Martin Paz is an Executive Officer at Alcresta Therapeutics, which develops enzyme-based therapeutic products for nutritional care in patients with rare diseases. He previously served as Chief Human Resources Officer at several multinational corporations.
RG
Robert GallottoinSenior Adviser & Co-founder2017–2018
DT
Daniel TasseinCEO & Chairman2016–2018Daniel Tasse is Executive Officer and Director of Alcresta Therapeutics, which develops enzyme-based therapeutic products for enterally fed patients with rare diseases. He has held executive leadership roles across drug, device, and healthcare delivery companies with international operations.
WS
William ScheinlerinChief Legal Officer
AM
Alexey MargolinNamed on SEC filing
Board
JL
Jeremy LackBoard director
SK
Stephen KraussBoard director
JT
SD
Steve DubinBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$75.9M disclosed across 4 rounds · 2016–2020
▶$10MraisedMar 2020 · 17 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen KrausDirector
- Anastasios KonidarisExecutive Officer, Director
- William ScheinlerExecutive Officer
- Alexey MargolinDirector
- Todd CreechDirector
- Steve DubinDirector
- Daniel OrlandoExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedJan 2019 · 19 investors · BiotechnologyRule 506(b)
▶$5MraisedJan 2019 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexey MargolinDirector
- Steve DubinDirector
- Anastasios KonidarisExecutive Officer, Director
- William ScheinlerExecutive Officer
- Stephen KrausDirector
- Garheng KongDirector
- Offering amount
- $25M
- Amount sold
- $5M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedSep 2017 · 13 investors · BiotechnologyRule 506(b)
▶$10MraisedSep 2017 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anastasios KonidarisExecutive Officer, Director
- Stephen KrausDirector
- Eric FirstExecutive Officer
- Garheng KongDirector
- William ScheinlerExecutive Officer
- Steve DubinDirector
- James TopperDirector
- Alexey MargolinDirector
- Daniel TasseExecutive Officer, Director
- Martin PazExecutive Officer
- James GamgortExecutive Officer
- Offering amount
- $35M
- Amount sold
- $10M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.9MraisedOct 2016 · 13 investors · BiotechnologyRule 506(b)
▶$50.9MraisedOct 2016 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeremy LackDirector
- Stephen KraussDirector
- Tasos KonidarisExecutive Officer
- James TopperDirector
- Steve DubinDirector
- Martin PazExecutive Officer
- Robert GallottoExecutive Officer
- Daniel TasseExecutive Officer, Director
- William ScheinlerExecutive Officer
- Alexey MargolinDirector
- Offering amount
- $50.9M
- Amount sold
- $50.9M
- Proceeds to insiders
- $1M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapMolina Healthcare12 shared keywordsMolina Healthcare is a Fortune 500 health care organization operating across multiple U.S. states. The company provides health insurance and related healthcare services to diverse populations.
Emblem Health11 shared keywordsEmblemHealth's Neighborhood Care is a health and wellness program offering free fitness classes, health education workshops, and community events to the public, while providing personalized insurance support and local resource connections to EmblemHealth members. The initiative serves entire communities with emphasis on preventive health and social determinants of well-being.
Companies competing with Alcresta for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Alcresta do?
- Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases. The company is based in Massachusetts and focuses on delivering novel enzymatic solutions within the biotechnology and pharmaceutical sector.
- Who are Alcresta's investors?
- Alcresta's investors include HealthQuest Capital, Bessemer Venture Partners, Frazier Life Sciences, Third Rock Ventures.
- How much funding has Alcresta raised?
- Alcresta has disclosed $75.9M raised across 4 rounds.
- Where is Alcresta headquartered?
- Alcresta is headquartered in Massachusetts, US.